Welcome to our dedicated page for Verona Pharma SEC filings (Ticker: VRNA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Verona Pharma’s SEC documents don’t just list numbers—they reveal how each Phase III readout, cash runway estimate, or licensing discussion can reshape the future of COPD treatment. Yet separating critical trial updates from 200-page technical appendices is time-consuming.
That’s why Stock Titan pairs every filing with AI-powered summaries that explain Verona Pharma SEC filings explained simply. Need the latest Verona Pharma quarterly earnings report 10-Q filing? Our engine extracts R&D spend, burn rate and milestone guidance in seconds. Curious about board decisions? The platform flags Verona Pharma proxy statement executive compensation details and contextualizes option awards against peer biotechs.
Real-time feeds surface Verona Pharma Form 4 insider transactions real-time, letting you see Verona Pharma insider trading Form 4 transactions moments after they hit EDGAR. Click once to view an AI summary that highlights buying or selling trends and links to deeper Verona Pharma executive stock transactions Form 4 analytics. When management issues an 8-K on topline efficacy, our system posts the document within minutes, with a note titled “Verona Pharma 8-K material events explained”.
Whether you’re preparing for FDA Advisory Committee chatter or modeling dilution risk, our coverage spans every form—S-1s, S-3s, 424Bs, plus the flagship Verona Pharma annual report 10-K simplified. Professionals use these insights to validate assumptions, track fundraising capacity, and benchmark trial timelines. If you’re still scrolling through PDFs, try understanding Verona Pharma SEC documents with AI and experience Verona Pharma earnings report filing analysis that saves hours and sharpens decisions.
Form 4 filed by David R. Ebsworth, Director of Verona Pharma plc (VRNA) dated 08/05/2025 reporting transactions on 08/01/2025. The report discloses a grant of RSUs covering 24,000 Ordinary Shares (presented as the Ordinary Share equivalent of ADS-based RSUs) and a mandatory "sell-to-cover" sale of 1,904 Ordinary Shares at $13.1437 per share to satisfy tax withholding upon vesting. The RSUs vest 25% on each of Aug 1, 2025; Nov 1, 2025; Feb 1, 2026; and May 1, 2026 and have no expiration. Following the reported transactions the filing shows direct beneficial ownership of 880,499 Ordinary Shares and indirect ownership of 617,600 Ordinary Shares via Ebsworth GmbH. Form signed by attorney-in-fact on 08/05/2025.
Form 4 filing for Verona Pharma plc (VRNA) by Director Anders Ullman reporting an RSU award and resulting holdings.
On 08/01/2025 Ullman received an award of 24,000 Restricted Share Units (RSUs) expressed as the equivalent number of Ordinary Shares underlying ADSs, at a reported price of $0. Each RSU represents a contingent right to receive one ADS; each ADS represents 8 Ordinary Shares. Following the transaction Ullman beneficially owns 358,856 Ordinary Shares (reported as 44,857 ADSs) and holds 72,000 derivative securities reported as RSUs. The RSUs have no expiration and vest 25% on Aug 1, 2025, Nov 1, 2025, Feb 1, 2026 and May 1, 2026, subject to continued service. Form signed by attorney-in-fact Andrew Fisher on 08/05/2025.
Merck Sharp & Dohme LLC has filed a DFAN14A on behalf of Verona Pharma (VRNA) as part of the ongoing merger process. The filing consists of an internal e-mail and video transcript sent 30 Jul 2025 to all Verona employees. Key takeaways:
- Deal timing: Merck reiterates that the acquisition is expected to close later in 2025, subject to Verona shareholder approval and sanction by the U.K. High Court.
- Work-force retention: Virtually every Verona employee (excluding some executives) will receive a retention agreement by end-Aug; signatures are due 19 Sep and are contingent on deal completion.
- Strategic rationale: Verona’s COPD drug Ohtuvayre is positioned as a critical growth driver within Merck’s multiyear optimisation initiative, underscoring the buyer’s commitment to invest in pipeline, products and people.
Verona Pharma plc (VRNA) – Form 4 insider filing
Chief Financial Officer Mark W. Hahn reported two equity transactions on 7 Jul 2025-8 Jul 2025.
- Equity award & conversion: 675,048 performance-based Restricted Share Units (RSUs) were granted after the Board confirmed that Q2 2025 performance metrics were met. On the same day 229,512 Ordinary Shares (≈28,689 ADSs) were issued on RSU conversion at a cost basis of $0.
- Tax withholding: 90,320 Ordinary Shares (≈11,290 ADSs) were automatically withheld at an effective price of $11.4413 to satisfy tax obligations; no open-market sale occurred.
- Post-transaction ownership: Hahn now holds 12,418,184 Ordinary Shares (≈1.55 million ADSs), all in direct ownership.
Because the RSUs vested only after Q2 targets were achieved, the filing signals that internal performance hurdles were met, a modestly positive data-point for investors. The net share movement (≈+139,000 Ordinary Shares) increases the CFO’s equity exposure, aligning his incentives with shareholders.
FAQ
What is the current stock price of Verona Pharma (VRNA)?
What is the market cap of Verona Pharma (VRNA)?
